XBiotech sinks on Phase III colorectal data

XBiotech Inc. (NASDAQ:XBIT) fell $8.10 (33%) to $16.80 on Tuesday after reporting results from a Phase

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE